RTP Mobile Logo

Friday, December 8, 2017, Atlanta, Georgia, 12:30 PM – 3:30 PM (Eastern Time)

Addressing Current Questions and Controversies in the Management of Lymphoma and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series)

A Friday Satellite Symposia Series Preceding the 59th ASH Annual Meeting & Exposition

Event Details

Atlanta Marriott Marquis
265 Peachtree Center Avenue
Atlanta, GA 30303
Hotel Phone: 404-521-0000

Event Times:
12:30 PM – 1:00 PM (Eastern Time) — Registration and Lunch Buffet
1:00 PM – 3:30 PM (Eastern Time) — Educational Meeting

Meeting Room:
Marquis Ballroom B-D (Marquis Level)

There is no registration fee for this event. However, preregistration is advised, as seating is limited.

Martin Dreyling, MD, PhD
Professor of Medicine
Department of Medicine III
University Hospital – LMU Munich
Munich, Germany

Jonathan W Friedberg, MD, MMSc
Samuel E Durand Professor of Medicine
Director, James P Wilmot Cancer Institute
University of Rochester
Rochester, New York

Craig Moskowitz, MD
Stephen A Greenberg Chair in Lymphoma Research
Clinical Director, Division of Hematologic Oncology
Attending Physician
Lymphoma and Adult BMT Services
Member, Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Medical College of Cornell University
New York, New York

Owen A O’Connor, MD, PhD
Professor of Medicine and
Developmental Therapeutics
Director, Center for Lymphoid Malignancies
Columbia University Medical Center
College of Physicians and Surgeons
NewYork-Presbyterian Hospital
New York, New York

Laurie H Sehn, MD, MPH
Centre for Lymphoid Cancer
BC Cancer Agency and
University of British Columbia
Vancouver, British Columbia, Canada

Neil Love, MD
Research To Practice
Miami, Florida


MODULE 1: Hodgkin Lymphoma (HL) — Dr Moskowitz

Faculty Presentation Topics

  • Potential clinical implications of the ECHELON-1 study evaluating brentuximab vedotin (BV) with AVD (doxorubicin/vinblastine/dacarbazine) versus ABVD (AVD with bleomycin) for patients with previously untreated advanced HL
  • Indications for and practical considerations with the use of BV as consolidation after autologous stem cell transplant
  • Available safety and efficacy data with anti-PD-1/PD-L1 antibodies in the management of relapsed/refractory (R/R) HL
  • Emerging data with and ongoing evaluation of anti-PD-1/PD-L1 antibodies in earlier lines of therapy and/or in combination with other systemic approaches

Sample Questions Contributed by Consulting Oncologists

  • What has been observed in terms of pulmonary toxicity in patients receiving anti-PD-1/PD-L1 antibodies?
  • Would you consider BV or a checkpoint inhibitor as first-line treatment for an older, frail patient with HL who is concerned about the toxicity of standard chemotherapy?
  • Can the bleomycin be dropped after several cycles in a patient experiencing a good response to ABVD, and what is the role of PET scanning in evaluating response in these patients?

MODULE 2: Chronic Lymphocytic Leukemia (CLL) — Dr Friedberg

Faculty Presentation Topics

  • Clinical, biologic and practical factors influencing the choice of evidence-based options for younger and older patients with newly diagnosed disease (FCR, bendamustine/rituximab [BR], ibrutinib, obinutuzumab/chemotherapy, et cetera)
  • Utility of existing and emerging biomarkers (del17p, IGVH mutations, TP53 mutations, complex karyotype, minimal residual disease, et cetera) and implications for clinical decision-making
  • Integration of novel agents (eg, idelalisib, acalabrutinib) into the management of R/R CLL

Sample Questions Contributed by Consulting Oncologists

  • How would you approach a patient with good disease control on ibrutinib who develops atrial fibrillation requiring long-term anticoagulation? 
  • What is the role of MRD testing in a patient with relapsed CLL and high-risk cytogenetics who is experiencing a prolonged response to therapy?
  • Are the faculty considering or using venetoclax for patients with non-del(17p) disease who experience relapse on ibrutinib, and if so, are they combining it with rituximab?

MODULE 3: Follicular Lymphoma (FL) — Dr Sehn

Faculty Presentation Topics

  • Efficacy and safety of obinutuzumab-based induction and maintenance therapy for patients with previously untreated FL
  • Available data with and current clinical role of the “R-squared” regimen of lenalidomide/rituximab for patients with R/R disease
  • Recent FDA approval of copanlisib for relapsed FL
  • Ongoing investigation of novel agents in FL in the front-line and R/R settings

Sample Questions Contributed by Consulting Oncologists

  • What is the optimal treatment for a patient with FL who experiences rapid tumor progression after receiving BR and 4 cycles of rituximab maintenance? 
  • Is the benefit observed with obinutuzumab in the GALLIUM study sufficient to justify its use as induction and maintenance therapy for patients with FL given the level of comfort that we currently have with rituximab?
  • Would you consider long-term rituximab maintenance in an older patient with low-grade FL who experiences a good response and resolution of B symptoms after 4 cycles of single-agent rituximab?

MODULE 4: Mantle Cell Lymphoma (MCL) — Dr Dreyling 

Faculty Presentation Topics

  • Available and emerging research information with novel agents as a component of induction and/or post-transplant maintenance therapy in MCL 
  • Clinical and biologic factors guiding the selection and sequence of systemic therapy for R/R MCL 
  • Mechanism of action and tolerability of the recently FDA-approved second-generation BTK inhibitor acalabrutinib
  • Mechanistic diversity among and available data with novel agents in development for MCL

Sample Questions Contributed by Consulting Oncologists

  • How will the eventual availability of novel agents as a component of induction treatment affect our approach to maintenance therapy and transplant?
  • Should patients who experience a response to front-line BR receive maintenance rituximab and, if so, for what duration? 
  • How do you best sequence ibrutinib versus lenalidomide versus bortezomib for relapsed MCL, and are the faculty using venetoclax in this setting?

MODULE 5: Diffuse Large B-Cell Lymphoma (DLBCL) and T-Cell Lymphoma (TCL) — Dr O’Connor

Faculty Presentation Topics

  • Recent FDA approval and emerging clinical role of CAR T-cell therapy for patients with DLBCL and other aggressive lymphomas 
  • Available and emerging research information with lenalidomide and ibrutinib in newly diagnosed and R/R DLBCL
  • Available safety and efficacy data with BV for patients with CD30-positive TCL
  • Patient- and/or disease-specific factors guiding the sequence and selection of belinostat, pralatrexate and romidepsin in T-cell lymphoma

Sample Questions Contributed by Consulting Oncologists

  • How close are we to CAR T-cell therapy becoming a mainstream option for patients? What centers have been activated, and is this something that patients can access without being placed on a waiting list? 
  • Outside a clinical trial setting, how do you typically manage “double-hit” DLBCL?
  • What is the optimal therapy for a patient with relapsed peripheral TCL after a 3-year response to cyclophosphamide/doxorubicin/etoposide/vincristine/prednisone (CHOEP)? 
  • Should CHOEP still be considered standard first-line therapy for elderly patients with TCL, or is it reasonable to administer palliative therapy with an agent such as romidepsin or pralatrexate?

CE Information

Target Audience:
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lymphoma and chronic lymphocytic leukemia (CLL).

Learning Objectives:
At the conclusion of this activity, participants should be able to:

  • Individualize the selection and sequence of systemic therapy for patients with newly diagnosed and relapsed/refractory (R/R) CLL, considering the patient’s clinical presentation, biomarker profile and psychosocial status.
  • Consider existing and emerging clinical research data in the formulation of therapeutic recommendations for patients with newly diagnosed and R/R diffuse large B-cell lymphoma, follicular lymphoma and mantle cell lymphoma.
  • Incorporate new therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
  • Assess the benefits and risks of evidence-based systemic treatment options to individualize and optimize the care of patients with T-cell lymphoma.
  • Compare and contrast the mechanisms of action, efficacy and safety of approved and investigational immune checkpoint inhibitors for the treatment of HL and non-Hodgkin lymphoma (NHL) to determine the current and/or potential utility of each in clinical practice.
  • Develop an understanding of the biologic rationale for and appreciate available efficacy and safety data with chimeric antigen receptor T-cell therapy, and identify patients with R/R B-cell cancers for whom this approach may be appropriate. 
  • Assess the ongoing clinical trials evaluating other novel investigational approaches for HL, NHL and CLL, and obtain consent from appropriate patients for study participation.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: medical oncology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP/Acerta Pharma, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology.


Atlanta Marriott Marquis
265 Peachtree Center Avenue
Atlanta, GA 30303
Hotel Phone: 404-521-0000

Meeting Room:
Marquis Ballroom B-D (Marquis Level)

The Atlanta Marriott Marquis hotel is conveniently located within 1 mile of the Georgia World Congress Center, where the ASH Annual Meeting is taking place.

ASH will provide complimentary shuttle service between official housing hotels and the Georgia World Congress Center on Friday, December 8. Service frequency will vary throughout the day between 6:30 AM and 10:30 PM. Look for detailed shuttle bus schedules in your hotel lobby.



Thank you for your interest in our CME program. At this time, online preregistration is closed for this event. Onsite registration will be open starting at 12:15 PM (local time) on Friday, December 8th. If you are interested in attending, please visit our registration desk located outside the Marquis Ballroom B-D (Marquis Level) at the Atlanta Marriott Marquis hotel (265 Peachtree Center Avenue, Atlanta, GA 30303).

If seats become available for the program, we will accept new registrations on a first come, first served basis. Please note, onsite registration does not guarantee participation in the session or meal service, and seating will be prioritized for clinicians in practice.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.


This educational session has been approved by ASH as part of the Friday Satellite Symposia educational schedule, and registration for this event is independent of registration for the ASH conference.